China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm Kactus Biosystems, a company specializing in target protein and raw enzyme production. The agreement pertains to the new gene editing tool enzyme, hfCas12Max. According to the terms, Kactus will secure an exclusive license to produce and sell hfCas12Max for grade proteins in Greater China, along with a general license for the production and sales of GMP grade products. HuidaGene is set to receive the corresponding commercial share of hfCas12Max.
Advantages of hfCas12Max Over Traditional CRISPR Systems
HfCas12Max has been developed using HuidaGene’s HGPRECISE (HuidaGene–Platform for Rational Engineering of CRISPR-Cas Identification by Synergic Expertise) platform. This cutting-edge enzyme boasts higher target editing activity and significantly lower off-target editing activity compared to the widely used CRISPR-Cas9 and Cas12a, Cas12b, and Cas12e systems. This advancement positions hfCas12Max as a potentially more precise and safer tool in the field of gene editing.-Fineline Info & Tech
